Search
Search Results
##search.searchResults.foundPlural##
-
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2735PDF: 937HTML: 9086Efremov 1: 288Efremov 2: 260 -
TYROSINE KINASE INHIBITORS AND INTERFERON
3069PDF: 1551HTML: 3107Cover Letter: 284 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4253PDF: 1675HTML: 9334Untitled: 363Untitled: 239Untitled: 228Untitled: 245Untitled: 237Untitled: 408 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3591PDF: 1706HTML: 4104 -
TYROSINE KINASE INHIBITORS AND PREGNANCY
3933PDF: 1822HTML: 2785 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
5256PDF: 3044HTML: 2389 -
DOWNREGULATION OF STEAROYL-COA DESATURASE 1 (SCD-1) PROMOTES RESISTANCE TO IMATINIB IN CHRONIC MYELOID LEUKEMIA Downregulation of Scd-1 in Chronic Myeloid Leukemia
1666PDF: 1362HTML: 548 -
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277961PDF: 1924HTML: 3920 -
GILTERITINIB (XOSPATA ®) IN TURKEY: EARLY ACCESS PROGRAM RESULTS Gilteritinib (XOSPATA ®) in Turkey
1681PDF: 1003Suppl. Files: 503HTML: 313 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2413PDF: 1721HTML: 765 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2460PDF: 1145HTML: 2042Characteristic of study group: 280 -
Ponatinib induced improvement of cutaneous lesions associated to accelerated phase of Ph-positive chronic myeloid leukemia
3064PDF: 770HTML: 1978figure 1: 249figure 2: 234 -
TRANSCRIPTOME ANALYSIS OF BETA-CATENIN-RELATED GENES IN CD34+ HAEMATOPOIETIC STEM AND PROGENITOR CELLS FROM PATIENTS WITH AML Transcriptome analysis of beta-catenin-related genes in AML
1265PDF: 1265Suppl. Files: 610HTML: 117 -
THE Co-Occurrence of Jak2/Calr-Positive Myeloproliferative Disorder and Bcr-Abl-Positive Chronic Myelogenous Leukaemia Treated with Combination of Tyrosine Kinase Inhibitors and Ruxolitinib. Dual Myeloid Disorder Treated with Two Drug Association
1252PDF: 1334HTML: 150 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1971PDF: 2179Suppl. Files: 300HTML: 126 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1483PDF: 514HTML: 18649Figure 1: 217Figure 2: 197Figure 3: 219Figure 4: 261Figure 5: 227 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
8020PDF: 2548HTML: 2184Table 1.: 290Table 2.: 312Table 3.: 275Table 4.: 281 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
4174PDF: 1154HTML: 3926Untitled: 210Cneo. Fig.1: 149Untitled: 141Untitled: 180Untitled: 181 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
6027PDF: 1636HTML: 1690Untitled: 296 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1810PDF: 1176HTML: 527 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1953PDF: 1284HTML: 376 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1491PDF: 1151HTML: 493 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2532PDF: 1959HTML: 1097 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3973PDF: 1754HTML: 120 -
Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature
2173PDF: 1041HTML: 1798Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated AML- IMAGES: 246 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1845PDF: 1181HTML: 201







